Background: The introduction of highly active antiretroviral therapy (HAART) has led to a marked reduction in Acquired Immune Deficiency Syndrome (AIDS) related morbidity and mortality. However, HAART has been reported to be associated with a number of side effects in human immunodeficiency virus (HIV) positive persons among which dyslipidemia and lipodystrophy are common metabolic disorders. Objective: To assess the prevalence and predictors of dyslipidemia among HAART and HAART naive HIV positive persons in Defense Hospital, Addis Ababa-Ethiopia. Methods: A facility based comparative cross-sectional study among 228 HIV positive persons was conducted from September to October 2013. Socio-demographic and clinical data were collected using structured questionnaires. Fasting venous blood sample was drawn for laboratory analysis. Lipid profiles were measured using clinical chemistry analyzer (HumStar80, USA). CD4 cell counting was done using BD FACS Count™ (BD, USA). Anthropometric measurement was done. Data was analyzed using SPSS version 20 for windows. Result: A total of 228, 114 on HAART and 114 HAART naïve HIV positive persons, were enrolled in the study. The overall prevalence of dyslipidemia was 63.6%. Prevalence of dyslipidemia in HAART naive and on HAART HIV positive persons was 61(53.5%) and 84(73.7%), respectively. The prevalence of TC≥200 mg/dl was 50% and 30%; HLD-c<40 mg/dl was 43.8% and 36%; LDL-c≥130mg/dl was 48.3% and 28.1%; and TG≥150 mg/dl 59.6% and 39% among on HAART and HAART naïve, respectively. Age greater than 40 years old (AOR = 3.27, 95% C.I: 1.47 - 7.25), blood pressure ≥ 140/90 (AOR = 16.13, 95% C.I: 5.81 - 44.75), being on HAART (AOR = 2.73, 95 % C.I: 1.35 - 5.53), and body mass index > 25kg/m2 (AOR = 1.92, 95 % C.I: 1.20 - 4.81) were identified as determinants of dyslipidemia. Conclusion: The mean value of lipid profile was significantly higher on HAART as compared to HAART naïve HIV positive persons. It is important to have well controlled cohort studies for the evaluation of long-term effects of HAART on lipid profiles.
| Published in | American Journal of Health Research (Volume 2, Issue 5) |
| DOI | 10.11648/j.ajhr.20140205.23 |
| Page(s) | 303-309 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2014. Published by Science Publishing Group |
Dyslipidemia, HAART, HIV /AIDS, Prevalence, Ethiopia
| [1] | A.S. Fauci, E. Brawnwald, D.L. Kasper, S.L. Hauser, D.L. Longo, J.L. Jameson, et al., “Harrison's Principles of Internal Medicine,” 17th ed., McGraw-Hill Medical Publishing Division: New York, 2008. |
| [2] | D. Rouleau, C. Fortin, B. Trotier, R. Lalonde, N. Lapointe, P. Cote, et al., “Antiretroviral therapy for adults infected with HIV: Guidelines for health care profesionals from Quebec HIV care commettee,” Can J Infect Dis Med Microbiol, Vol. 22(2), pp.52-60, 2011. |
| [3] | T. Gsponer, M. Petersen, M. Egger, S. Phiri, M.H. Maathuis, A. Boulle, et al., “The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring,” AIDS, Vol. 26(1), pp57–65, 2012. |
| [4] | W.T. Enanoria, C. Ng, S.R. Saha, Jr. JM. Colford, “Treatment outcomes after highly active antiretroviral therapy: a meta-analysis of randomised controlled trials,” Lancet Infect Dis, Vol.4 (7), pp.414–25, 2004. |
| [5] | WHO, “Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach,” Geneva, World Health Organization, 2006. |
| [6] | C. Lewden, T. May, E. Rosenthal, C. Burty, F. Bonnet, D. Costagliola, et al., “Changes in causes of death among adults infected by HIV between 2000 and 2005: The “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic),” J Acquir Immune Defic Syndr, 48(5):590-8, 2008. |
| [7] | C. Grunfeld, “Dyslipidemia and its treatment in HIV infection,” Top HIV.Med, Vol. 18, pp. 112–18, 2010. |
| [8] | JG.Troll, “Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection," Curr Atheroscler Rep, Vol.13 (1), pp. 51-6, 2011. |
| [9] | Australian Institute of Health and Welfare 2010, “Australia’s health 2010,” Australia’s health series no. 12. Cat. No. AUS 122.Canberra: AIHW. |
| [10] | W.M. El-Sadr, C.M. Mullin, A. Carr, C. Gibert, C. Rappoport, F. Visnegarwala, et al., “Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort,” HIV Med. Vol. 6(2), pp.114-21, 2005. |
| [11] | J.E. Gallant, S. Staszewski, A.L. Pozniak, E. DeJesus, JMAH Suleiman, MD. Miller, et al., “Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial,” JAMA, Vol.292 (2), pp.191-201, 2004. |
| [12] | K. Anastos, D. Lu, Q. Shi, PC. Tien, RC. Kaplan, NA. Hessol, et al., “Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens,” J Acquir Immune Defic Syndr, Vol.45 (1), pp. 34–42, 2007. |
| [13] | V. M. Vander, J.J. Kastelein, R.L. Murphy, F. Van Leth, C. Katlama, A. Horban, et al., “Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti atherogenic lipid profile,” AIDS, Vol. 15(18), pp. 2407–2414, 2001. |
| [14] | A. Carr, K. Samaras, S. Burton, M. Law, J. Freund, D.J. Chisholm, et al., “A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors,” AIDS, Vol. 12(7), pp.F51-8, 1998. |
| [15] | S.P. Jones, O. Janneh, D.J. Back, M. Pirmohamed, “Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors,” Antivir Ther (Lond), Vol. 10(2), pp. 207-13, 2005. |
| [16] | J. Young, R. Weber, M. Rickenbach, H. Furrer, E. Bernasconi, B. Hirschel, et al., “Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study,” Antivir Ther (Lond), Vol. 10(5), pp.585-91, 2005. |
| [17] | S. Rasheed, J.S. Yan, A. Lau, A.S. Chan, “HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study,” PLoS ONE. Vol. 3(8):e3003, 2008. |
| [18] | A. Mastroianni, “Emergence of Sjogren’s syndrome in AIDS patients during highly active antiretroviral therapy,” AIDS. Vol.18 (9), pp. 1349-52, 2004. |
| [19] | M. Shahmanesh, H. Jaleel, Y. De Silva, “Protease inhibitor related type III hyper lipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype,” Sex Transm Infect, Vol. 77, pp. 283-6, 2001. |
| [20] | M.S. Rhee, J.A. Hellinger, S. Sheble-Hall, C.J. Cohen, D.J. Greenblatt, “Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir),” J Clin Pharmacol, Vol. 50(4), pp.392-400, 2010. |
| [21] | E.R. Feeney, P.WG. Mallon, “HIV and HAART-Associated Dyslipidemia,” Open Cardiovasc Med J, Vol.5, pp.49-63, 2011. |
| [22] | Ministry of health and social services directorate of special programmes, “National Guidelines for Antiretroviral Therapy,” 3rd ed., 2010. WHO, “HIV Care & PMTCT in Resource-Limited Settings: Monthly Intelligence Report,” Vol.6 (1), 2010. |
| [23] | E.W. Pefura Yone, A.F. Betyoumin, A.P. Kengne, F.J. Kaze Folefack, J.Ngogang, “First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study,” AIDS Res Ther. Vol. 8, pp. 33, 2011. |
| [24] | EM. Manuthu, M.D. Joshi, G.N. Lule, E. Karari, “Prevalence of dyslipidemia and dysglycaemia in HIV infected patients,” East Afr Med J, Vol. 85(1), pp.10-7, 2008. |
| [25] | National Cholesterol Education Program (NCEP), “Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report,” Circulation, Vol.106(25), pp.3143-421, 2002. |
| [26] | F.F. Akinola, A.A. Akinjinmi, O.O. Oguntibeju, “Effect of Combined Antiretroviral Therapy on Selected Trace Elements and CD4+T-cell Count in HIV Positive Persons in an African Setting,” J AIDS Clinic Res, Vol.3(1850. doi: 10.4172/2155-6113.1000185), 2012. |
| [27] | EFR. Silva, K.C. Bassichetto, D.S. Lewi, “Lipid profile, cardiovascular risk and AIDS,”Arq Bras Cardiol, Vol. 93(2), pp.107-111, 2009. |
| [28] | A. Tadewos, Z. Addis, H. Ambachew, S.Banerjee, “Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study,” AIDS Res Ther, Vol. 9(1), pp. 31, 2012. |
| [29] | T. Berhane, A. Yami, F. Alemseged, T. Yemane, L. Hamza, M. Kassim, et al., “Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on Highly Active Anti-Retroviral treatment in Jimma, South West Ethiopia,” Pan Afr Med J, Vol.13, pp.43, 2012. |
| [30] | C. Padmapriyadarsini, S. Ramesh Kumar, N. Terrin, G. Narendran, P.A. Menon, G. Ramachandran, et al., “Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India,” Clin Infect Dis, Vol.52(4), pp.540-6, 2011. |
APA Style
Habtamu Wondiferaw Bayenes, Mehidi Kassim Ahmed, Tilahun Yemane Shenkute, Yaregal Asres Ayenew, Lealem Gedefaw Bimerew. (2014). Prevalence and Predictors of Dyslipidemia on HAART and HAART Naive HIV Positive Persons in Defense Hospital, Addis Ababa, Ethiopia. American Journal of Health Research, 2(5), 303-309. https://doi.org/10.11648/j.ajhr.20140205.23
ACS Style
Habtamu Wondiferaw Bayenes; Mehidi Kassim Ahmed; Tilahun Yemane Shenkute; Yaregal Asres Ayenew; Lealem Gedefaw Bimerew. Prevalence and Predictors of Dyslipidemia on HAART and HAART Naive HIV Positive Persons in Defense Hospital, Addis Ababa, Ethiopia. Am. J. Health Res. 2014, 2(5), 303-309. doi: 10.11648/j.ajhr.20140205.23
AMA Style
Habtamu Wondiferaw Bayenes, Mehidi Kassim Ahmed, Tilahun Yemane Shenkute, Yaregal Asres Ayenew, Lealem Gedefaw Bimerew. Prevalence and Predictors of Dyslipidemia on HAART and HAART Naive HIV Positive Persons in Defense Hospital, Addis Ababa, Ethiopia. Am J Health Res. 2014;2(5):303-309. doi: 10.11648/j.ajhr.20140205.23
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajhr.20140205.23,
author = {Habtamu Wondiferaw Bayenes and Mehidi Kassim Ahmed and Tilahun Yemane Shenkute and Yaregal Asres Ayenew and Lealem Gedefaw Bimerew},
title = {Prevalence and Predictors of Dyslipidemia on HAART and HAART Naive HIV Positive Persons in Defense Hospital, Addis Ababa, Ethiopia},
journal = {American Journal of Health Research},
volume = {2},
number = {5},
pages = {303-309},
doi = {10.11648/j.ajhr.20140205.23},
url = {https://doi.org/10.11648/j.ajhr.20140205.23},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajhr.20140205.23},
abstract = {Background: The introduction of highly active antiretroviral therapy (HAART) has led to a marked reduction in Acquired Immune Deficiency Syndrome (AIDS) related morbidity and mortality. However, HAART has been reported to be associated with a number of side effects in human immunodeficiency virus (HIV) positive persons among which dyslipidemia and lipodystrophy are common metabolic disorders. Objective: To assess the prevalence and predictors of dyslipidemia among HAART and HAART naive HIV positive persons in Defense Hospital, Addis Ababa-Ethiopia. Methods: A facility based comparative cross-sectional study among 228 HIV positive persons was conducted from September to October 2013. Socio-demographic and clinical data were collected using structured questionnaires. Fasting venous blood sample was drawn for laboratory analysis. Lipid profiles were measured using clinical chemistry analyzer (HumStar80, USA). CD4 cell counting was done using BD FACS Count™ (BD, USA). Anthropometric measurement was done. Data was analyzed using SPSS version 20 for windows. Result: A total of 228, 114 on HAART and 114 HAART naïve HIV positive persons, were enrolled in the study. The overall prevalence of dyslipidemia was 63.6%. Prevalence of dyslipidemia in HAART naive and on HAART HIV positive persons was 61(53.5%) and 84(73.7%), respectively. The prevalence of TC≥200 mg/dl was 50% and 30%; HLD-c 25kg/m2 (AOR = 1.92, 95 % C.I: 1.20 - 4.81) were identified as determinants of dyslipidemia. Conclusion: The mean value of lipid profile was significantly higher on HAART as compared to HAART naïve HIV positive persons. It is important to have well controlled cohort studies for the evaluation of long-term effects of HAART on lipid profiles.},
year = {2014}
}
TY - JOUR T1 - Prevalence and Predictors of Dyslipidemia on HAART and HAART Naive HIV Positive Persons in Defense Hospital, Addis Ababa, Ethiopia AU - Habtamu Wondiferaw Bayenes AU - Mehidi Kassim Ahmed AU - Tilahun Yemane Shenkute AU - Yaregal Asres Ayenew AU - Lealem Gedefaw Bimerew Y1 - 2014/10/20 PY - 2014 N1 - https://doi.org/10.11648/j.ajhr.20140205.23 DO - 10.11648/j.ajhr.20140205.23 T2 - American Journal of Health Research JF - American Journal of Health Research JO - American Journal of Health Research SP - 303 EP - 309 PB - Science Publishing Group SN - 2330-8796 UR - https://doi.org/10.11648/j.ajhr.20140205.23 AB - Background: The introduction of highly active antiretroviral therapy (HAART) has led to a marked reduction in Acquired Immune Deficiency Syndrome (AIDS) related morbidity and mortality. However, HAART has been reported to be associated with a number of side effects in human immunodeficiency virus (HIV) positive persons among which dyslipidemia and lipodystrophy are common metabolic disorders. Objective: To assess the prevalence and predictors of dyslipidemia among HAART and HAART naive HIV positive persons in Defense Hospital, Addis Ababa-Ethiopia. Methods: A facility based comparative cross-sectional study among 228 HIV positive persons was conducted from September to October 2013. Socio-demographic and clinical data were collected using structured questionnaires. Fasting venous blood sample was drawn for laboratory analysis. Lipid profiles were measured using clinical chemistry analyzer (HumStar80, USA). CD4 cell counting was done using BD FACS Count™ (BD, USA). Anthropometric measurement was done. Data was analyzed using SPSS version 20 for windows. Result: A total of 228, 114 on HAART and 114 HAART naïve HIV positive persons, were enrolled in the study. The overall prevalence of dyslipidemia was 63.6%. Prevalence of dyslipidemia in HAART naive and on HAART HIV positive persons was 61(53.5%) and 84(73.7%), respectively. The prevalence of TC≥200 mg/dl was 50% and 30%; HLD-c 25kg/m2 (AOR = 1.92, 95 % C.I: 1.20 - 4.81) were identified as determinants of dyslipidemia. Conclusion: The mean value of lipid profile was significantly higher on HAART as compared to HAART naïve HIV positive persons. It is important to have well controlled cohort studies for the evaluation of long-term effects of HAART on lipid profiles. VL - 2 IS - 5 ER -
Email: